Disc Medicine (IRON) management will participate in fireside chats at four investor conferences from November 9 through November 18, 2026.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
The events are hosted by Guggenheim, Stifel, UBS and Jefferies. Management will also hold investor meetings at these conferences and the Truist BioPharma Symposium on November 12. Live webcasts and subsequent replays of the fireside chats will be available through the company's investor relations website.
Details
News Market Reaction – IRON
On Nov 2, the day this news came out, IRON closed 2.75% below the previous close.
Data tracked by StockTitan Argus for the Nov 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that company management will participate in fireside chats at upcoming investor conferences:
- Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9th at 10:30 a.m. ET
- Stifel 2026 Healthcare Conference on Thursday, November 12th at 2:00 p.m. ET
- UBS Global Biopharma Conference on Tuesday, November 17th at 3:40 a.m. ET / 8:40 a.m. GMT
- Jefferies London Global Healthcare Conference on Wednesday, November 18th at 6:30 a.m. ET / 11:30 a.m. GMT
Disc management will be participating in investor meetings during the above conferences, as well as during the Truist BioPharma Symposium in New York on Thursday, November 12.
Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Peg Rusconi
Deerfield Group
[email protected]
Kevin Lui
Precision AQ
[email protected]